- INmune Bio (INMB +4.2%) announces data presentation from Phase Ib study of XPro1595 in patients with Alzheimer’s. Data were presented at International Conference on Alzheimer’s Drug Discovery meeting.
- The Phase Ib study continues to enroll patients.
- In July, the company announced positive prelim data study that showed a 40.6% reduction in major white matter anterior/posterior tract important for language and short-term memory.
- https://seekingalpha.com/news/3619842-inmune-bio-to-present-interim-data-from-early-stage-alzheimer-s-study
Monday, October 5, 2020
INmune Bio to present interim data from early-stage Alzheimer’s study
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.